Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings
JCO Global Oncology · 2025
DOI: 10.1200/go.24.00217 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Elen Baloyan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yerevan State Medical University, Yerevan, Armenia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years. METHODS This is a retrospective study with data from three oncology centers in Armenia: “Muratsan” Hospital of Yerevan State Medical University, Mikaelyan institute of surgery, and Yeolyan Hematology and Oncology Center. The information was obtained from the medical records of the patients with pancreatic cancer treated at these centers during January 1, 2010-January 1, 2022. Log-rank test and Kaplan-Meier curves were used for survival analysis. Cox regression analysis was performed for identification of main prognostic factors. RESULTS Of 70 patients involved in the final analysis, 45.7% was female. The median age at diagnosis was 63 years. The median follow-up time was 11 months (range, 2-146). A total of 11.4% of patients had stage I-II, 27.1% had stage III, and 60% had stage IV disease. The main independent prognostic factor for overall survival (OS) was the TNM stage, whereas grade of the tumor was not significant. The median OS was 11 months (range, 2-169 months): In stages I-III, patients who had surgery (44.4%) lived significantly longer than those who did not (20 v 11 months; P = .008). Main chemotherapy regimens were 5-fluorouracil, oxaliplatin, folinic acid and irinotecan (41.4%) and gemcitabine plus capecitabine (38.6%). No significant survival difference was found between these groups (13 v 11 months; P = .162). CONCLUSION Survival of patients with pancreatic cancer in Armenia is dismal, not exceeding 1 year. Hopefully, further research in the field and new treatment modalities will improve the situation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Oncology, Yerevan State Medical University, Yerevan, Armenia.
- Adults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, Armenia.
- Immune Oncology Research Institute, Yerevan, Armenia.
- Department of Chemotherapy, Mikaelyan Institute of Surgery, Yerevan, Armenia.
- Alikhanyan National Science Laboratory, Yerevan, Armenia.
- City University of Hong Kong, Kowloon, Hong Kong.
ORCID-Profile: Elen Baloyan, Lilit Harutyunyan, Vardan Bardakhchyan, Jemma Arakelyan, Amalya Sargsyan, Mariam Mailyan, Gevorg Tamamyan, Samvel Bardakhchyan
Zitieren
APA
Baloyan, E., Zohrabyan, D., Safaryan, L., Avagyan, A., Harutyunyan, L., Bardakhchyan, V., Arakelyan, J., Sargsyan, A., Harutyunyan, M., Mailyan, M., Tamamyan, G., & Bardakhchyan, S. (2025). Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings. JCO Global Oncology. https://doi.org/10.1200/go.24.00217
Vancouver
Baloyan E, Zohrabyan D, Safaryan L, Avagyan A, Harutyunyan L, Bardakhchyan V, et al. Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings. JCO Global Oncology. 2025. doi:10.1200/go.24.00217
BibTeX
@article{Baloyan2025,
author = {Baloyan, Elen and Zohrabyan, Davit and Safaryan, Liana and Avagyan, Armen and Harutyunyan, Lilit and Bardakhchyan, Vardan and Arakelyan, Jemma and Sargsyan, Amalya and Harutyunyan, Martin and Mailyan, Mariam and Tamamyan, Gevorg and Bardakhchyan, Samvel},
title = {Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go.24.00217}
}
EUVIMED